Rule of five violations among the FDA-approved small molecule protein kinase inhibitors
Because genetic alterations including mutations, overexpression, translocations, and dysregulation of protein kinases are involved in the pathogenesis of many illnesses, this enzyme family is the target of many drug discovery programs in the pharmaceutical industry. Overall, the US FDA has approved...
Saved in:
Main Author: | Robert Roskoski, Jr (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2023-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update
by: Robert Roskoski, Jr
Published: (2024) -
Cost in the United States of FDA-approved small molecule protein kinase inhibitors used in the treatment of neoplastic and non-neoplastic diseases
by: Robert Roskoski, Jr
Published: (2024) -
Small molecule protein kinase inhibitors approved by regulatory agencies outside of the United States
by: Robert Roskoski Jr
Published: (2023) -
Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis
by: Robert Roskoski, Jr
Published: (2023) -
A Comprehensive Review of Clinical Cardiotoxicity Incidence of FDA-Approved Small-Molecule Kinase Inhibitors
by: Ying Jin, et al.
Published: (2020)